A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL
This study is to evaluate the efficacy and safety of Bortezomib plus GDP in the treatment of non-GCB DLBCL patients.
Diffuse Large B-cell Lymphoma
DRUG: Bortezomib|DRUG: Gemcitabine|DRUG: Dexamethasone|DRUG: Cisplatin
Response rate, 28 days as one cycle, Every 2 cycles during treatment and then every 3 months for 2 years
Progression free survival, 1 year|Overall survival, 1 year|Safety as assessed using the CTCAE, 28 days as one cycle, Days 1 of each course and 4-6 weeks after final treatment
This study is to evaluate the efficacy and safety of Bortezomib plus GDP in the treatment of non-GCB DLBCL patients.